The Lancet: Targeted drug doubles progression free survival in Hodgkin lymphoma

A phase 3 trial of brentuximab vedotin , the first new drug for Hodgkin lymphoma in over 30 years, shows that adults with hard-to-treat Hodgkin lymphoma given BV immediately after stem cell transplant survived without the disease progressing for twice as long as those given placebo . The findings, published in The Lancet , are potentially practice changing for this young cancer population who have exhausted other treatment options and for whom prognosis is poor.

http://ift.tt/1BWMfGg